Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03701321
Recruitment Status : Suspended (Other - FDA Partial Clinical Hold)
First Posted : October 10, 2018
Last Update Posted : April 18, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : October 31, 2023
  Estimated Study Completion Date : October 31, 2023